Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans

B. P. Schick, Joel Gradowski, J. D. San Antonio, J. Martinez

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Patients undergoing anticoagulation with unfractionated heparin, low molecular weight heparin, or danaparoid may experience excess bleeding which requires reversal of the anticoagulant agent. Protamine is at present the only agent available for reversal of unfractionated heparin. Protamine is not effective in patients who have received low molecular weight heparin or danaparoid. We have developed a series of peptides based on consensus heparin binding sequences (Verrecchio et al., J Biol Chem 2000; 275: 7701-7707) that are capable of neutralizing the anti-thrombin activity of unfractionated heparin in vitro, the anti-factor Xa activity of unfractionated heparin, Enoxaparin (Lovenox) and danaparoid (Orgaran) in vitro and the anti-Factor Xa activity of Enoxaparin in vivo in rats. These peptides may serve as alternatives for Protamine reversal of UFH and may be useful for neutralization of enoxaparin and danaparoid in humans.

Original languageEnglish (US)
Pages (from-to)482-487
Number of pages6
JournalThrombosis and Haemostasis
Volume85
Issue number3
StatePublished - Apr 3 2001

Fingerprint

Enoxaparin
Glycosaminoglycans
Anticoagulants
Heparin
Protamines
Peptides
Factor Xa
Low Molecular Weight Heparin
Thrombin
danaproid
Hemorrhage
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans. / Schick, B. P.; Gradowski, Joel; San Antonio, J. D.; Martinez, J.

In: Thrombosis and Haemostasis, Vol. 85, No. 3, 03.04.2001, p. 482-487.

Research output: Contribution to journalArticle

@article{b793f6ed939140ddbb61467f78bbe53b,
title = "Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans",
abstract = "Patients undergoing anticoagulation with unfractionated heparin, low molecular weight heparin, or danaparoid may experience excess bleeding which requires reversal of the anticoagulant agent. Protamine is at present the only agent available for reversal of unfractionated heparin. Protamine is not effective in patients who have received low molecular weight heparin or danaparoid. We have developed a series of peptides based on consensus heparin binding sequences (Verrecchio et al., J Biol Chem 2000; 275: 7701-7707) that are capable of neutralizing the anti-thrombin activity of unfractionated heparin in vitro, the anti-factor Xa activity of unfractionated heparin, Enoxaparin (Lovenox) and danaparoid (Orgaran) in vitro and the anti-Factor Xa activity of Enoxaparin in vivo in rats. These peptides may serve as alternatives for Protamine reversal of UFH and may be useful for neutralization of enoxaparin and danaparoid in humans.",
author = "Schick, {B. P.} and Joel Gradowski and {San Antonio}, {J. D.} and J. Martinez",
year = "2001",
month = "4",
day = "3",
language = "English (US)",
volume = "85",
pages = "482--487",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "3",

}

TY - JOUR

T1 - Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans

AU - Schick, B. P.

AU - Gradowski, Joel

AU - San Antonio, J. D.

AU - Martinez, J.

PY - 2001/4/3

Y1 - 2001/4/3

N2 - Patients undergoing anticoagulation with unfractionated heparin, low molecular weight heparin, or danaparoid may experience excess bleeding which requires reversal of the anticoagulant agent. Protamine is at present the only agent available for reversal of unfractionated heparin. Protamine is not effective in patients who have received low molecular weight heparin or danaparoid. We have developed a series of peptides based on consensus heparin binding sequences (Verrecchio et al., J Biol Chem 2000; 275: 7701-7707) that are capable of neutralizing the anti-thrombin activity of unfractionated heparin in vitro, the anti-factor Xa activity of unfractionated heparin, Enoxaparin (Lovenox) and danaparoid (Orgaran) in vitro and the anti-Factor Xa activity of Enoxaparin in vivo in rats. These peptides may serve as alternatives for Protamine reversal of UFH and may be useful for neutralization of enoxaparin and danaparoid in humans.

AB - Patients undergoing anticoagulation with unfractionated heparin, low molecular weight heparin, or danaparoid may experience excess bleeding which requires reversal of the anticoagulant agent. Protamine is at present the only agent available for reversal of unfractionated heparin. Protamine is not effective in patients who have received low molecular weight heparin or danaparoid. We have developed a series of peptides based on consensus heparin binding sequences (Verrecchio et al., J Biol Chem 2000; 275: 7701-7707) that are capable of neutralizing the anti-thrombin activity of unfractionated heparin in vitro, the anti-factor Xa activity of unfractionated heparin, Enoxaparin (Lovenox) and danaparoid (Orgaran) in vitro and the anti-Factor Xa activity of Enoxaparin in vivo in rats. These peptides may serve as alternatives for Protamine reversal of UFH and may be useful for neutralization of enoxaparin and danaparoid in humans.

UR - http://www.scopus.com/inward/record.url?scp=0035080696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035080696&partnerID=8YFLogxK

M3 - Article

VL - 85

SP - 482

EP - 487

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 3

ER -